184 related articles for article (PubMed ID: 35348393)
1. Does
Jonsson J; Hemmingsson O; Strengbom R; Axelsson J; Riklund K; Nyström H
Scand J Surg; 2022; 111(1):14574969221083144. PubMed ID: 35348393
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis exploring the role of PET and PET-CT in the management of potentially resectable colorectal cancer liver metastases.
Daza JF; Solis NM; Parpia S; Gallinger S; Moulton CA; Belley-Cote EP; Levine MN; Serrano PE
Eur J Surg Oncol; 2019 Aug; 45(8):1341-1348. PubMed ID: 30928334
[TBL] [Abstract][Full Text] [Related]
3. Positron Emission Tomography Combined With Computed Tomography vs. No Positron Emission Tomography Combined With Computed Tomography for the Management of Patients With Resectable Colorectal Cancer Liver Metastases and Synchronous Extrahepatic Disease.
Serrano PE; Gu CS; Moulton CA; Gallinger S
Am Surg; 2021 Sep; 87(9):1431-1437. PubMed ID: 33345573
[TBL] [Abstract][Full Text] [Related]
4. Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT.
Wildi SM; Gubler C; Hany T; Petrowsky H; Clavien PA; Jochum W; Gerlach T; Fried M; Mullhaupt B
J Clin Ultrasound; 2008 Jan; 36(1):20-6. PubMed ID: 17937421
[TBL] [Abstract][Full Text] [Related]
5. The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases.
Zubeldia JM; Bednarczyk EM; Baker JG; Nabi HA
Cancer Biother Radiopharm; 2005 Aug; 20(4):450-6. PubMed ID: 16114993
[TBL] [Abstract][Full Text] [Related]
6. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings.
Lubezky N; Metser U; Geva R; Nakache R; Shmueli E; Klausner JM; Even-Sapir E; Figer A; Ben-Haim M
J Gastrointest Surg; 2007 Apr; 11(4):472-8. PubMed ID: 17436132
[TBL] [Abstract][Full Text] [Related]
7. Respiratory gated and prolonged acquisition 18F-FDG PET improve preoperative assessment of colorectal liver metastases.
Revheim ME; Haugvik SP; Johnsrud K; Mathisen Ø; Fjeld JG; Skretting A
Acta Radiol; 2015 Apr; 56(4):397-403. PubMed ID: 24682406
[TBL] [Abstract][Full Text] [Related]
8. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.
Ruers TJ; Langenhoff BS; Neeleman N; Jager GJ; Strijk S; Wobbes T; Corstens FH; Oyen WJ
J Clin Oncol; 2002 Jan; 20(2):388-95. PubMed ID: 11786565
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer.
Briggs RH; Chowdhury FU; Lodge JP; Scarsbrook AF
Clin Radiol; 2011 Dec; 66(12):1167-74. PubMed ID: 21867996
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases.
Truant S; Huglo D; Hebbar M; Ernst O; Steinling M; Pruvot FR
Br J Surg; 2005 Mar; 92(3):362-9. PubMed ID: 15672427
[TBL] [Abstract][Full Text] [Related]
11. Role of FDG-PET in surgical management of patients with colorectal liver metastases.
Teague BD; Morrison CP; Court FG; Chin VT; Costello SP; Kirkwood ID; Maddern GJ
ANZ J Surg; 2004 Aug; 74(8):646-52. PubMed ID: 15315564
[TBL] [Abstract][Full Text] [Related]
12. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
[TBL] [Abstract][Full Text] [Related]
13. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.
Lai DT; Fulham M; Stephen MS; Chu KM; Solomon M; Thompson JF; Sheldon DM; Storey DW
Arch Surg; 1996 Jul; 131(7):703-7. PubMed ID: 8678767
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of
Grut H; Dueland S; Line PD; Revheim ME
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):218-225. PubMed ID: 29026950
[TBL] [Abstract][Full Text] [Related]
15. Positron Emission Tomography-Computed Tomography (PET-CT) Versus No PET-CT in the Management of Potentially Resectable Colorectal Cancer Liver Metastases: Cost Implications of a Randomized Controlled Trial.
Serrano PE; Gafni A; Gu CS; Gulenchyn KY; Julian JA; Law C; Hendler AL; Moulton CA; Gallinger S; Levine MN
J Oncol Pract; 2016 Jul; 12(7):e765-74. PubMed ID: 27328792
[TBL] [Abstract][Full Text] [Related]
16. Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases.
Georgakopoulos A; Pianou N; Kelekis N; Chatziioannou S
Clin Imaging; 2013; 37(3):536-41. PubMed ID: 23116727
[TBL] [Abstract][Full Text] [Related]
17. Importance of 18F-FDG PET/CT to select patients with nonresectable colorectal liver metastases for liver transplantation.
Grut H; Revheim ME; Line PD; Dueland S
Nucl Med Commun; 2018 Jul; 39(7):621-627. PubMed ID: 29683930
[TBL] [Abstract][Full Text] [Related]
18. Controversies in the management of colorectal liver metastases: role of PET and PET/CT.
Wiering B; Vogel WV; Ruers TJ; Oyen WJ
Dig Surg; 2008; 25(6):413-20. PubMed ID: 19212113
[TBL] [Abstract][Full Text] [Related]
19. Does positron emission tomography/computed tomography change management in colorectal cancer?
Falconer R; Connor S; Balasingam A; Eglinton T
ANZ J Surg; 2018 Apr; 88(4):E248-E251. PubMed ID: 27788564
[TBL] [Abstract][Full Text] [Related]
20. Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases.
Wiering B; Adang EM; van der Sijp JR; Roumen RM; de Jong KP; Comans EF; Pruim J; Dekker HM; Ruers TJ; Krabbe PF; Oyen WJ
Nucl Med Commun; 2010 Nov; 31(11):938-44. PubMed ID: 20856152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
